IP Library Granted Patent US 10,166,104
Granted Patent B2
US 10,166,104 · App. 15/421,983 · Granted Jan 1, 2019

Calcium phosphate polymer composite and method

Inventors: Mei Wei (Coventry, CT); James R. Olson (Norwich, CT); Montgomery T. Shaw (Coventry, CT)
Assignees: TELEFLEX MEDICAL INCORPORATED; THE UNIVERSITY OF CONNECTICUT
A61F2/28A61F2/30965A61L27/20A61L27/425A61F2/3094A61F2/30767A61F2/468A61F2002/2817A61F2002/30032A61F2002/30062A61F2002/30224A61F2002/30235A61F2002/30293A61F2002/30677A61F2002/30914A61F2002/30957A61F2210/0004A61F2230/0069A61F2230/0091A61F2250/003A61F2310/00293A61F2310/00365A61F2310/00796A61L27/46A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,104
App. No.
15/421,983
Granted
Jan 1, 2019
Kind
B2
Abstract

A bone-repair composite includes a core and a sheath. The core is a first primary unit including a combination of a first set of yarns coated with a calcium phosphate mineral layer. The first set of yarns being made from a first group of one or more polymers. The sheath is a second primary unit a combination of a second set of yarns or one or more polymer coatings. The second set of yarns being made from a second group of one or more polymers, wherein the composite is made by covering the core with the sheath, and the composite is compression molded to allow the sheath to bond to the core. The bone-repair composite has a bending modulus comparable to that of a mammalian bone, such that the ratio of the core to the sheath is provided to maximize the mechanical strength of the bone-repair composite to mimic the mammalian bone.

Claims (9)

1. A bone replacement composite comprising:

a poly(ε-caprolactone) (PCL) matrix;

a multitude of poly(L-lactic) acid (PLLA) fibers disposed within the PCL matrix, the multitude of PLLA fibers being aligned along a common axis; and

a calcium phosphate mineral layer coating each of the PLLA fibers, the calcium phosphate mineral layer being between 25% by weight and 43% by weight of the bone replacement composite, wherein a crystalline orientation of the calcium phosphate mineral layer is aligned with the common axis, wherein the bone replacement composite is a rod or bar-shaped composite configured to replace a portion of a bone in a patient and wherein a bending modulus of the bone-repair composite is at least 3 GPa.

2. The bone replacement composite according to claim 1 , wherein a ratio of PLLA fibers to PCL matrix is 6:1 wt/wt.

3. The bone replacement composite according to claim 2 , further comprising filing materials including drugs or bioactive agents, wherein the filling materials is used as a binding material or for drug release.

4. The bone replacement composite according to claim 2 , further comprising fibers made from materials selected from a group consisting of collagen, hyaluronans, fibrin, chitosan, alginate, silk, polyesters, polyethers, polycarbonates, polyamines, polyamides, co-polymers, polyglycolic acid (PGA), poly(D,L-lactide-coglycolide) (PLGA), and poly(ε-caprolactone) (PCL).

5. The bone replacement composite according to claim 2 , wherein the calcium phosphate mineral layer is selected from a group consisting of ion-substituted apatite, calcium phosphate, carbonate hydroxyapatite, fluorinated hydroxyapatite, chlorinated hydroxyapatite, silicon-containing hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, monotite, dicalcium phosphate, dicalcium phosphate dihydrate, octacalcium phosphate, calcium phosphate monohydrate, alpha-tricalcium phosphate, beta-tricalcium phosphate, amorphosus calcium phosphate, biphasic calcium phosphate, calcium deficient hydroxyapatite, precipitated hydroxyapatite, and oxyapatite.

6. The bone replacement composite according to claim 2 , wherein the calcium phosphate mineral layer is anchored to the polymer surface by electrostatic, coordinative, ionic or chemical tethering.

Assignments (3)
SECURITY INTEREST Recorded Oct 3, 2019
From: TELEFLEX MEDICAL INCORPORATED
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 050620/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2018
From: WEI, MEI; OLSON, JAMES R.; SHAW, MONTGOMERY T.
To: TELEFLEX MEDICAL INCORPORATED; THE UNIVERSITY OF CONNECTICUT
Reel/Frame 047464/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2018
From: WEI, MEI; OLSON, JAMES R; SHAW, MONTGOMERY T
To: TELEFLEX MEDICAL INCORPORATED; THE UNIVERSITY OF CONNECTICUT
Reel/Frame 047466/0826 →
Continuity (3)
Continuation 11790345 · Apr 25, 2007
Provisional Application 60794518 · Apr 25, 2006
Related Publication 20170348104A1 · Dec 7, 2017
Cited By (1)
US 12,496,567